Synopsis:

Dive into this episode of Biotech 2050 where host Rahul Chaturvedi interviews Jeb Keiper, CEO of Nimbus Therapeutics. Discover Jeb's fascinating journey from MIT chemist to industry leader, and the unique strategies that have driven Nimbus's success. Jeb discusses the evolution of biotech financing, the importance of taking bold risks, and the innovative approaches Nimbus employs in drug development. He also shares insights on building a resilient team, navigating challenging capital markets, and fostering a collaborative ecosystem in biotech. This episode provides valuable lessons for aspiring biotech leaders and a deep dive into the intricacies of managing a cutting-edge biotech company.

Biography:

Jeb Keiper, M.S., M.B.A., has served as our President and Chief Executive Officer and as a member of our board of directors since October 2018. He previously served as Chief Business Officer from November 2014 to October 2018 and as Chief Financial Officer from February 2017 to October 2018. Since joining Nimbus, Mr. Keiper has overseen the discovery and development of three programs into clinical testing across a range of indications, over $400M raised in equity funding, executed deals worth over $7B, and the return of over $4B in gains back to equity holders.
Prior to joining Nimbus, Mr. Keiper served as the Vice President of Business Development at GSK Oncology (a subsidiary of GlaxoSmithKline plc (NYSE: GSK)) from March 2011 to October 2014, where he was responsible for identifying and concluding several critical collaborations for GSK in Oncology, including the Novartis-GSK Oncology integration, and spent a decade at GSK in various business development leadership roles. Prior to GSK, Mr. Keiper was a consultant at McKinsey & Company starting in September 2000-2002, then September 2004 to 2005, after having started his career as a pharmaceutical chemist at Pfizer Inc. (NYSE: PFE) in 1998.
Mr. Keiper currently serves as a member of the board of directors at private biotechnology companies Cardurion Pharmaceuticals, Inc., and ROME Therapeutics, Inc.
Mr. Keiper received two B.S. degrees, one in Chemistry and one in Chemical Engineering, as well as an M.S. in Chemical Engineering from the Massachusetts Institute of Technology, and an M.B.A. from the MIT Sloan School of Management with joint program in Biomedical Enterprises with the Harvard Medical School.